News from janssen pharmaceutical companies of johnson & johnson A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 24, 2021, 14:22 ET Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA by ViiV Healthcare for Expanded Use of CABENUVA (rilpivirine and cabotegravir) as an HIV Treatment for Use Every Two Months

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U....

Feb 08, 2021, 17:00 ET Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS...

Feb 08, 2021, 17:00 ET Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which...

Feb 02, 2021, 07:32 ET Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American...

Jan 28, 2021, 22:45 ET New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in...

Jan 21, 2021, 22:57 ET Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA...

Jan 19, 2021, 16:24 ET In Case You Missed It: Multimedia Now Available to Learn More About Light Chain (AL) Amyloidosis and a New Treatment Option

Learn about light chain (AL) amyloidosis and a new treatment option for this rare and serious blood cell disorder. Experience the interactive...

Jan 15, 2021, 17:49 ET Multimedia Now Available: Learn More About Light Chain (AL) Amyloidosis and a New Treatment Option

Learn about light chain (AL) amyloidosis and a new treatment option for this rare and serious blood cell disorder. Experience the interactive...

Jan 15, 2021, 17:21 ET DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO®...

Jan 12, 2021, 18:28 ET Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral...

Dec 21, 2020, 07:00 ET Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

he Janssen Pharmaceutical Companies of Johnson & Johnson announced today the initiation of a rolling submission of its Biologics License Application...

Dec 05, 2020, 17:00 ET Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of...

Dec 05, 2020, 15:17 ET Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation...

Dec 05, 2020, 15:00 ET Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study...

Dec 04, 2020, 12:30 ET Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Regimen After First or Subsequent Relapse in Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX FASPRO® ...

Nov 13, 2020, 17:55 ET Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial (NCT03252847) of its...

Nov 12, 2020, 07:00 ET Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of regulatory applications to the U.S. Food and Drug...

Nov 09, 2020, 08:00 ET New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart...

Nov 06, 2020, 07:00 ET TREMFYA® (guselkumab) Reduced Fatigue over 52 Weeks in Adult Patients with Psoriatic Arthritis in Two Phase 3 Clinical Trials

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which...

Nov 05, 2020, 08:30 ET Janssen Highlights Data from Rheumatology Portfolio During the American College of Rheumatology Convergence 2020 Virtual Scientific Program

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the latest research from its expanding rheumatology portfolio will be...

Nov 05, 2020, 07:00 ET Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations,...

Nov 02, 2020, 07:00 ET Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a supplemental New Drug Application (sNDA) to...

Oct 26, 2020, 08:30 ET Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S....

Oct 19, 2020, 08:00 ET Janssen Demonstrates Strong Commitment To Research And Development Of Therapies For Inflammatory Bowel Diseases With Nine Data Presentations At ACG 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that data from nine company-sponsored abstracts will be presented at the...

Sep 30, 2020, 08:58 ET SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® ...